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Sarcoidosis is a systemic inflammatory granulomatous disease affecting multiple organs, including liver, spleen, heart, eyes, 
and skin. Liver involvement is reported in 11.5% of cases and many studies have reported on the association between hepatitis 
C virus infection and sarcoidosis. However, the role of hepatitis B virus (HBV) infection as a trigger for sarcoidosis has never 
been reported. We describe a case of hepatic sarcoidosis in a patient with chronic hepatitis B infection, with a possible link be-
tween the two. It is the first case report of a patient with interferon-α-naïve chronic HBV infection presenting with hepatic sar-
coidosis accompanied by portal hypertension and liver cirrhosis.  (J Rheum Dis 2015;22:200-204)
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INTRODUCTION
Sarcoidosis is an autoimmune disease which is charac-
terized by systemic non-caseating granuloma in multiple 
organs [1,2]. It has been reported to be able to occur in ev-
ery race and age, and the incidence ranges 1 to 40 cases 
per 100,000 persons worldwide [2]. However, the in-
cidence of sarcoidosis in Asian is less than that of 
Caucasian: 1 to 2 cases per 100,000 in Japan and 0.13 cas-
es per 100,000 in Korea [3,4]. Although sarcoidosis can 
be suspected when patients present disease-related clin-
ical and radiologic features, typical histologic findings are 
essential to make a diagnosis [5].
Sarcoidosis commonly involves lungs and lymph nodes 
up to 90% and it can also affect almost all organs includ-
ing liver, spleen, heart, eyes and skin [2]. Liver involve-
ment can be found in 11.5% of the cases [6], and it is usu-
ally asymptomatic. Only 5% to 30% patients experience 
atypical symptoms such as nausea, vomiting and abdomi-
nal pain [7]. The progressive complication like liver cir-
rhosis is rarely presented at a rate less than 1% [2].
There have been several reports regarding the associa-
tion between hepatitis C virus (HCV) and hepatic 
sarcoidosis. Interferon-α (INF-α), which was used to 
treat HCV, was first considered to induce hepatic 
sarcoidosis. And then there were accumulating reports 
that HCV itself can be an initiating factor for hepatic sar-
coidosis [8]. However the association between the devel-
opment of sarcoidosis and hepatitis B virus (HBV) was 
not clarified and there was no case report on sarcoidosis 
in patients with chronic HBV infection who were not 
treated by INF-α. Hence, we first describe a patient with 
INF-α-naïve chronic HBV infection presenting hepatic 
sarcoidosis accompanied by portal hypertension and liver 
cirrhosis.
CASE REPORT
A 49-year-old woman with chronic HBV infection was 
referred to our hospital for loss of appetite and mild 
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Figure 1.  Abdomen sonogram 
(A) and abdomen computed to-
mography (CT) scan (B). 
Sonogram (A) reveals coarse pa-
renchymal echogenicity of the 
liver. CT scan (B) shows hetero-
geneous enhancement in the en-
larged liver and the spleen. 
Table 1. Laboratory data
Variable
Patient’s
result
Reference range
White cell count (/μL)
Hemoglobin (g/dL)
Platelet count (/μL)
Prothrombin time (s)
ESR (mm/h)
AST (IU/L)
ALT (IU/L)
Total protein (g/dL)
Albumin (g/dL)
Total bilirubin (mg/dL)
Gamma-GT (IU/L)
LDH (IU/L)
ALP (IU/L)
HBs Ag
HBe Ag
Anti HBe
HBV-RQ PCR (IU/mL)
Anti HCV
2,940
11.8
119,000
12.10
12.0
44
22
8.7
3.2
0.7
175
277
296
Positive
Negative
Positive
60.3
Negative
4,000~10,800
12.0~16.0
150,000~400,000
9.2~12.3
0.0~20.0
13.0~34.0
5.0~46.0
6.0~8.0
3.3~5.3
0.4~1.5
7.0~35.0
119~247
32~93
Negative
Negative
Negative
<20
Negative
Ag: antigen, ALP: alkaline phosphatase, ALT: alanine tran-
saminase, AST: aspartate transaminase, ESR: erythrocyte
sedimentation rate, GT: glutamyl transpeptidase, HBe: 
hepatitis B e, HBs: hepatitis B surface, HBV: hepatitis B virus, 
HCV: hepatitis C virus, LDH: lactate dehydrogenase, RQ PCR:
real-time quantitative polymerase chain reaction.
ab.dominal bloating and discomfort. She was diagnosed 
with HBV infection 10 years ago, but she has been on reg-
ular check-ups without the treatment for chronic HBV in-
fection so far. It was assumed that she had been infected 
with HBV by perinatal transmission as her mother and 
siblings had also been diagnosed with HBV infection. 
Other than B-viral hepatitis, she had no medical history. 
Physical examination revealed mild tenderness on right 
upper quadrant area of abdomen without rigidity. Liver 
was slightly palpated below the margin of right rib. 
Laboratory results are shown in Table 1.
The abdomen sonogram showed that parenchymal 
echogenicity of the liver was coarse without space occu-
pying lesion and the spleen was enlarged upto 12.63 cm 
(Figure 1A). Abdomen computed tomography (CT) scan 
revealed hepatosplenomegaly with heterogeneous en-
hancement and multiple lymph node enlargements 
around aorto-caval, para-aortic and peri-pancreatic space 
(Figure 1B). Liver stiffness measurement by transient 
elastography (FibroscanⓇ; Echosens, Paris, France) was 
24.2 kPa which is compatible with liver fibrosis at stage 4. 
The esophagogastroduodenoscopy was also done and it 
showed esophageal varix (small straight esophageal var-
ix, F1), which is a clinical complication of portal 
hypertension. 
Although she had been stable with chronic hepatitis B 
infection and lab findings were within normal range, the 
CT scan showed hepatosplenomegaly and multiple 
lymph node enlargements. Therefore, liver biopsy was 
needed to exclude other causes. Histology finding re-
vealed chronic granulomatous inflammation showing 
multifocal multinucleated giant cells (Figure 2A). It did 
not show any necrosis in the granuloma, so sarcoidosis 
and drug reaction could be suspected. However, we could 
conclude the histology finding as a sarcoidosis because 
asteroid bodies were noted (Figure 2B). Acid fast bacilli 
stain and periodic acid Schiff stain were negative, there-
fore the possibility of mycobacterial infection or fungal 
infection was low (Figure 2C and 2D).
Positron emission tomography (PET) scan was also 
done and it showed numerous hyper-metabolic foci in the 
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Figure 2.  Liver biopsy showing the non-caseating granuloma (arrows) (A) and asteroid body (B). Special staining for acid fast bacilli
(AFB) (C) and periodic acid Schiff (PAS) (D) were negative (A: H&E, ×100; B: H&E, ×400; C: AFB, ×400; D: PAS, ×400). 
Figure 3. Positron emission tomography scan with multiple 
uptakes in the liver, spleen, lymph nodes, and bones.
liver and spleen, multiple lymph nodes uptake and hy-
per-metabolic foci in bones including L3 vertebra, left 
iliac bone, sacrum and right proximal femur (Figure 3). 
Since thrombocytopenia abruptly occurred and pro-
gressed in addition to increased bone uptake on PET scan, 
bone marrow biopsy was done and there were no abnor-
mal findings. Thrombocytopenia might have been due to 
the liver cirrhosis. However, other manifestations of liver 
cirrhosis such as hyperbilirubinemia, hypoalbuminemia 
and prothrombin time prolongation were not remarkable. 
Therefore we suspected that hepatic sarcoidosis with 
marked splenomegaly might have induced the thrombo-
cytopenia [9].
Under the diagnosis of sarcoidosis, auto-immune mark-
ers and angiotensin-converting enzyme (ACE) level were 
checked. ACE level was elevated to 180 U/L (20 to 70 
U/L) and auto-immune markers including antinuclear 
antibody and rheumatoid factor were negative. 
She was diagnosed with sarcoidosis involving liver, lung 
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Figure 4. Chest computed tomography (CT) scans (A, B) and abdominal CT scans (C, D). CT scans at the time of diagnosis (A, C)
showing multiple perilymphatic nodules in both lungs (arrows) and heterogeneous enhancement in liver and spleen with 
hepatosplenomegaly. CT scans (B, D) taken after steroid treatment, revealing near total resolution of perilymphatic nodules and de-
creased size of liver and spleen.
and multiple lymph nodes, but no other organ involve-
ment was found in such as eyes, skin or joints. She began 
to receive prednisolone at a dose of 30 mg/d. Follow-up 
CT scan was performed and it revealed improvement of 
sarcoidosis in liver as well as lymph nodes (Figure 4). The 
laboratory results were all within normal reference range. 
Prednisolone was tapered to a dose of 16 mg/d on the last 
visit. 
DISCUSSION
So far, there have been many reports that described the 
association between sarcoidosis and HCV. The first case 
was reported by Blum et al. [10] in 1993. Also, IFN-α for 
the treatment of HCV was believed to provoke the devel-
opment of sarcoidosis by inducing various autoimmune 
conditions and disorders of immune regulation [11]. In 
1999, Belgodere et al. [12] first reported a case of a HCV 
patient with sarcoidosis who had never been treated with 
IFN-α. It showed that IFN-α therapy may activate the 
development of sarcoidosis, but HCV infection itself also 
can induce sarcoidosis. 
On the other hand, the report regarding the association 
between sarcoidosis and HBV is very rare; to our knowl-
edge, there was only one case report by Husa et al. [13] in 
2002. In that report, sarcoidosis was developed after the 
initiation of IFN-α for HBV treatment. But so far, there 
was no case report on sarcoidosis in patients with chronic 
HBV infection who were not treated by INF-α.
In this case, the patient had been diagnosed with chronic 
HBV infection, but had never been treated by drugs in-
cluding IFN-α. Thus we guessed the possible link be-
tween hepatic sarcoidosis and HBV infection. 
So far, there are a number of reports about the relation-
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ship between sarcoidosis and HCV infection. However, 
the studies regarding HBV infection is scarce. We spec-
ulate that the different cytokine profiles in HBV and HCV 
infection might be the reason for this different incidence 
of sarcoidosis. For example, higher amounts of IFN-γ are 
secreted in HCV infection than in HBV infection [14]. 
And in the pathogenesis of sarcoidosis, high expression 
of T helper 1 cytokines such as IFN-γ and interleukin-2 
is noted [15]. 
However, the exact mechanism still remains unclear due 
to the lack of reports. But it can be reasonably assumed 
that the alterations in the pool of cytokines and immune 
cells caused by HBV infection may have a vicious influ-
ence on the immune regulation and in turn it can be a trig-
ger for granuloma formation. 
SUMMARY
This report describes the first case of hepatic sarcoidosis 
accompanied by portal hypertension and liver cirrhosis in 
a patient with INF-α-naïve chronic HBV infection. 
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